Health-care companies rose as traders rotated into defensive sectors due to volatility in oil and Treasury markets.
Eli Lilly, one of the leaders in the GLP-1 boom, said a weight-loss drug based on a separate mechanism showed promise in a clinical trial. Retatrutide mimics the action of two hormones.
Japanese drugmaker Kissei Pharmaceutical said doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago that clinicians avoid new prescriptions following 20 deaths among people taking the medicine.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
